HLB PharmaceuticalHLB제약
047920 · KOSDAQ · ₩047920 · HLB제약
₩9,510▼ ₩440 (4.42%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 46.1% | 51.8% | 63.2% | 61.0% | 59.6% | 56.3% |
| Operating margin | 0.7% | 0.5% | 1.1% | −14.4% | −6.0% | 0.8% |
| Net margin | 1.1% | 2.2% | 1.5% | −14.3% | −11.0% | −21.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +22.6% | +50.0% | +0.8% | +26.5% | +71.0% | — |
| Operating income growth | +75.8% | −27.8% | +107.5% | −203.6% | −1,423.7% | — |
| Net income growth | −39.7% | +126.3% | +110.4% | −65.0% | +11.0% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 2.2% | 3.8% | 2.0% | −22.3% | −14.3% | −16.9% |
| Return on assets | 1.6% | 2.8% | 1.3% | −13.7% | −8.7% | −10.4% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 36.2% | 36.4% | 35.7% | 60.3% | 65.5% | 62.8% |
| Net debt to equity | −3.1% | −5.7% | −6.0% | 13.0% | 16.3% | 29.9% |
| Current ratio | 188.4% | 193.6% | 164.1% | 146.4% | 113.4% | 113.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: HLB Pharmaceutical / HLB제약 / 047920 / KRX:047920
Source: KRX statistical information